期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

急性髓细胞性白血病(AML)中IL-3Rα基因的表达及意义

Expression of IL-3Rα in Acute Myeloid Leukemia(AML) and its Significance
原文传递
导出
摘要 目的:检测白介素-3受体α亚基(IL-3Rα)在急性髓细胞性白血病(acute myeloid leukemia,AML)中的表达,研究其在AML发病和预后评估中的意义。方法:应用逆转录-聚合酶链反应(RT-PCR)法检测57例AML患者IL-3Rα的表达,其中包括52例初治和复发患者(6例M1、28例M2、10例M3、3例M4、5例M5)及5例缓解患者,另10例正常人作为对照。结果:①10例正常人和5例AML缓解患者未检测到IL-3Rα表达。②52例初治和复发的AML患者中IL-3Rα阳性表达21例,占40.38%,M1～M5各型患者的阳性率差异无显著性(P>0.05)。初治和复发AML患者之间IL-3Rα阳性表达无明显差异(P>0.05)。③AML患者的IL-3Rα阳性表达与外周血白细胞计数、骨髓中原始细胞比例、CD34阳性表达有关(P<0.05)。④AML患者中IL-3Rα阳性表达的患者CR率低于阴性者(P<0.05)。结论:①IL-3Rα在AML发病中有一定作用。②IL-3Rα基因可作为AML预后不良的一个指标。 Objective： To investigate the expression and significance of IL-3Rα in 57 paitients with acute myeloid leukemia（AML）.Methods： RT-PCR method was perfomed to examine the expression of IL-3Rα in bone marrow or peripheral blood mononuclear cells from 57 paitients with AML.The paitients included 52 newly diagnosed and relapse paitients（6 M1,28 M2,10 M3,3 M4,5 M5） and 5 CR patients.10 healthy subjects were used as control group.Results： ①5 CR patients didn’t express IL-3Rα mRNA.②The percentage of IL-3Rα mRNA expression in AML was 40.38%.IL-3Rα mRNA was expressed in all AML subtypes,and there was no difference among AML subtypes.In AML paitients,there was no difference between newly diagnosed and relapse patients.③In AML patients,the expression of IL-3Rα mRNA related to white blood count,blast cells ratio and CD34 positive expression（P〈0.05）.④The CR rate of AML patients who expressed IL-3Rα was significantiy lower than that of who didn’t express IL-3Rα（P〈0.05）.Conclusions： ①IL-3Rα gene might play an important role in the pathogenesis of AML.②IL-3Rα gene may be a poor prognostic factor in AML.
作者 宋玉华 彭鹏 邱少敏 王清波 谈国蕾
机构地区 东南大学医学院附属南京市第二医院肿瘤科
出处 《现代生物医学进展》 CAS 2012年第19期3632-3634,3627,共4页 Progress in Modern Biomedicine
关键词 白介素-3受体α亚基(IL-3Rα) 急性髓细胞性白血病 The interleukin-3 receptor α chain（IL-3Rα） Acute myeloid leukemia（AML）
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Sisk T J, Roys S, Chang CH. Self-Association of C TA and Its Transactivation Potential [J]. Molecular and Cellular Biology,2001,21 (15):4919-4928.
  • 2Casoli C, De Lerma Barbaro A, Pilotti E, et al. The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2[J]. Blood,2004, 103(3):995-1001.
  • 3Raval A, Weissman JD, Howcroft TK, et al. The GTP-binding domain of class II transactivator regulates its nuclear export [J]. J Immunol, 2003,170(2):922-930.
  • 4Hake SB, Mastemak K, Kammerbauer C, et al. C II TA Leucine-Rich Repeats Control Nuclear Localization, In Vivo Recruitment to the Major Histocompatibility Complex (MHC) Class II Enhanceosome, and MHC Class II Gene Transactivation [J]. Molecular and Cellular Biology,2000,20(20):7716-7725.
  • 5Cressman DE, William J. O~ Connor, Susanna F. Greer, et al. Mechanisms of nuclear import and export that control the subcellular localization of class II transactivator [J]. J Immunol,2001,167(7):3626 -3634.
  • 6Li GX, Harton JA, Zhu XS, et al. Downregulation ofC II TA Function by Protein Kinase A (PKA)-Mediated Phosphorylation: Mechanism of Prostaglandin E, Cyclic AMP, and PKA Inhibition of Class II Major Histocompatibility Complex Expression in Monocytic Lines [J]. Mol- ecular and Cellular Biology,2001,21(14):4626-4635.
  • 7Zhu XS, Linhoff MW, Li GX, et al. Transcriptional Scaffold: CIITA Interacts with NF-Y, RFX, and CREB To Cause Stereospecific Regul- ation of the Class II Major Histocompatibility Complex Promoter [J]. Molecular and Cellular Biology,2000,20(16):6051-6061.
  • 8Harton JA, Ting PY. Class II Transactivator: Mastering the Art of Major Histocompatibility Complex Expression [J]. Molecular and Cellular Biology.2000.20( 17):6185-6194.
  • 9Holling TM, Stoep N, Quinten E, et al. Activated Human T Cells Accomplish MHC Class II Expression Through T Cell-Specific Occupation of Class II Transactivator Promoter III [J]. The Journal of Immunology,2002,168:763-770.
  • 10Athena WW, Ghosh N, Karen P. McKinnon, et al. Regulation and Specificity of MHC2TA Promoter Usage in Human Primary T Lymphocytes and Cell Line [J]. The Journal of Immunology,2002,169:3112-3119.

二级参考文献8

  • 1Chin KC,Li G,Ting JP.Activation and transdominant suppression of MHC clssⅡand HLA-DMB promoters by a series of C-terminal classⅡtransactivator deletion mutants. J Immunol . 1997
  • 2Benichou,G.Direct and inditect antigen recognition: the pathways to allograft immune rejection. Frontiers in Bioscience . 1999
  • 3Fairchild,P.J.Presentation of antigenic peptides by products of the major histocompatibility complex, J. Peptide Science . 1998
  • 4Boss,J. M.Regulation of transcription of MHC class Ⅱ genes. Current Opinion in Immunology . 1997
  • 5Muhlethaler-Mottet A,Steimle V.Expression of MHC class Ⅱ mole-cules in difierent cellular and functional compartments is controlled by differential usage of multiple promoters of transactivator CⅡ TA. EMBO Journal . 1997
  • 6Steimle, V,Otten, L. A,Zufferey, M.Complementation cloning of an MHC class Ⅱ transactivator mutated in hereditary MHC class Ⅱ deficiency (or bare Iymphocyte syndrome). Cell . 1993
  • 7Chang, C. H,Flavell, R. A.Class Ⅱ transactivator regulates the expression of multiple genes involved in antigen presentation. The Journal of Experimental Medicine . 1995
  • 8Brodsky, F. M,Lem, L,Bresnaham, P.A. et al.Antigen processing and presentation. Tissue Antigens .

共引文献1

现代生物医学进展
2012年 第19期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部